1. Heeringa J, van der Kuip DA, Hofman A et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27(8): 949–953.
2. Caldeira D, David C, Sampaio C. Rate versus rhythm control in atrial fibrillation and clinical outcomes: Updated systematic review and meta-analysis of randomized controlled trials. Arch Cardiovasc Dis 2012; 105(4): 226–238.
3. Van Gelder IC, Wyse DG, Chandler ML et al. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace 2006; 8(11): 935–942.
4. Marshall DA, Levy AR, Vidaillet H et al. Cost-effectiveness of rhythm versus rate control in atrial fibrillation. Ann Intern Med 2004; 141(9): 653–661.
5. Mason PK, Wood MA, Lake D et al. Influence of the randomized trials, AFFIRM and RACE, on the management of atrial fibrillation in two University Medical Centers. Am J Cardiol 2005; 95(10): 1248–1250.
6. Corley SD, Epstein AE, DiMarco JP et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004; 109(12): 1509–1513.
7. Guglin M, Chen R, Curtis AB. Sinus rhythm is associated with fewer heart failure symptoms: insights from the AFFIRM trial. Heart Rhythm 2010; 7(5): 596–601.
8. Vidaillet H, Granada JF, Chyou PH et al. A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med 2002; 113(5): 365–370.
9. Dulli DA, Stanko H, Levine RL. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology 2003; 22(2): 118–123.
10. Waldo AL. Anticoagulation: stroke prevention in patients with atrial fibrillation. Med Clin North Am 2008; 92(1): 143–159.
11. Verma A, Debruyne P, Nardi S et al. ERACE Investigators. Evaluation and reduction of asymptomatic cerebral embolism in ablation of atrial fibrillation, but high prevalence of chronic silent infarction: results of the evaluation of reduction of asymptomatic cerebral embolism trial. Circ Arrhythm Electrophysiol 2013; 6(5): 835–842.
12. Sramko M, Peichl P, Wichterle D et al. A novel biomarker-based approach for the detection of asymptomatic brain injury during catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2014; 25(4): 349–354.
13. Santangeli P, Di Biase L, Bai R et al. Atrial fibrillation and the risk of incident dementia: a meta-analysis. Heart Rhythm 2012; 9(11): 1761–1768.
14. Stefansdottir H, Arnar DO, Aspelund T et al. Atrial fibrillation is associated with reduced brain volume and cognitive function independent of cerebral infarcts. Stroke 2013; 44(4): 1020–1025.
15. Efimova I, Efimova N, Chernov V et al. Ablation and pacing: improving brain perfusion and cognitive function in patients with atrial fibrillation and uncontrolled ventricular rates. Pacing Clin Electrophysiol 2012; 35(3): 320–326.
16. de la Torre JC. Cardiovascular risk factors promote brain hypoperfusion leading to cognitive decline and dementia. Cardiovasc Psychiatry Neurol 2012; 2012: 367516. Dostupné z DOI: <http://dx.doi.org/10.1155/2012/367516>.
17. Lishmanov A, Chockalingam P, Senthilkumar A et al. Tachycardia-induced cardiomyopathy: evaluation and therapeutic options. Congest Heart Fail 2010; 16(3): 122–126.
18. Gupta S, Figueredo VM. Tachycardia mediated cardiomyopathy: pathophysiology, mechanisms, clinical features and management. Int J Cardiol 2014; 172(1): 40–46.
19. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003; 91(6A): 2D-8D.
20. Bardai A, Blom MT, van Hoeijen DA et al. Atrial fibrillation is an independent risk factor for ventricular fibrillation: a large-scale population-based case-control study. Circ Arrhythm Electrophysiol 2014; 7(6): 1033–1039.
21. Reinier K, Marijon E, Uy-Evanado A et al. The association between atrial fibrillation and sudden cardiac death: the relevance of heart failure. JACC Heart Fail 2014; 2(3): 221–227.
22. Calkins H, Reynolds MR, Spector P et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol 2009; 2(4): 349–361.
23. Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33(21): 2719–2747.
24. Calkins H, Kuck KH, Cappato R et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 2012; 14(10): 528–606.
25. Sramko M, Peichl P, Wichterle D et al. Clinical value of assessment of left atrial late gadolinium enhancement in patients undergoing ablation of atrial fibrillation. Int J Cardiol 2015; 179: 351–357.
26. Hussein AA, Saliba WI, Martin DO et al. Natural history and long-term outcomes of ablated atrial fibrillation. Circ Arrhythm Electrophysiol 2011; 4(3): 271–278.
27. Deshmukh A, Patel NJ, Pant S et al. In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93 801 procedures. Circulation 2013; 128(19): 2104–2112.
28. Aldhoon B, Wichterle D, Peichl P et al. Complications of catheter ablation for atrial fibrillation in a high-volume centre with the use of intracardiac echocardiography. Europace 2013; 15(1): 24–32.